Company
Omniose
Omniose is an early-stage biotechnology company developing polysaccharide conjugate vaccines against serious bacterial threats using its proprietary bioconjugation platform.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Headquarters
- St. Louis, United States
- Founded
- 2016
- Legal name
- Omniose
Claim, correct or request removal
Record updated 28 September 2026
About
We are expanding the range of bacterial targets that can be addressed with bioconjugate vaccines. Bioconjugation relies on single cells that simultaneously produce a polysaccharide antigen along with an engineered carrier protein and a conjugating enzyme to precisely link them together. This is a much simpler process than conventional chemical conjugation methods and has the potential to produce higher quality vaccines. However, the enzymes used for bioconjugation thus far could only address a limited range of bacterial targets.
Funding snapshot
- Total raised
- $6.6MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Grant, $3M2023-09-27
Funding rounds
- Grant
- $3M2023-09-27, Company stated
- Grant
- $3.6M2022-10-11, Company stated
Loading relationship preview